Abstract
No data are available on the efficacy and safety of a combination of fondaparinux and thrombolysis in the setting of high to intermediate risk pulmonary embolism (PE). Patients submitted to thrombolysis and fondaparinux, presenting with ≥1 of the following criteria were included: (1) cardiogenic shock, (2) syncope, (3) ≥1 proximal thrombo-embolus at CT scan, (4) positive troponin test, (5) echocardiographic findings indicating right ventricular (RV) dysfunction. In-hospital results included death, recurrent PE, persistent RV dysfunction at 48 h echocardiography, bleeding complications. Twenty seven patients were included; 22 received a 2 h infusion of rt-PA and 5 received a 2 h infusion of streptokinase. Ten patients presented with cardiogenic shock (37%), 8 with syncope (30%), all had RV dysfunction. 82% of patients had an uneventful in-hospital course. One patient died during hospital stay from refractory shock. Thrombolysis failed in 2 patients (7%), requiring successful rescue surgical embolectomy. Bleeding events occurred in 2 patients (7%), of whom 1 required blood transfusion. Despite the small sample size, our data suggest that fondaparinux procures adequate tolerability compared to standard current therapy in combination with thrombolysis in high to intermediate risk PE.
Similar content being viewed by others
References
Buller HR, Davidson BL, Decousus H et al (2004) Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med 140:867–873
Buller HR, Davidson BL, Decousus H et al (2003) Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med 349:1695–1702. doi:10.1056/NEJMe038112
Turpie AG, Bauer KA, Eriksson BI et al (2002) Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 162:1833–1840. doi:10.1001/archinte.162.16.1833
Torbicki A, Perrier A, Konstantinides S et al (2008) Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 29:2276–2315
Yusuf S, Mehta SR, Chrolavicius S et al (2006) Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 295:1519–1530. doi:10.1001/jama.295.13.joc60038
Meyer G, Collignon MA, Guinet F et al (1990) Comparison of perfusion lung scanning and angiography in the estimation of vascular obstruction in acute pulmonary embolism. Eur J Nucl Med 17:315–319. doi:10.1007/BF01268022
Meneveau N, Schiele F, Metz D et al (1998) Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 31:1057–1063. doi:10.1016/S0735-1097(98)00068-0
Meneveau N, Seronde MF, Blonde MC et al (2006) Management of unsuccessful thrombolysis in acute massive pulmonary embolism. Chest 129:1043–1050. doi:10.1378/chest.129.4.1043
Wan S, Quinlan DJ, Agnelli G et al (2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 110:744–749. doi:10.1161/01.CIR.0000137826.09715.9C
Konstantinides S, Geibel A, Heusel G et al (2002) Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med 347:1143–1150. doi:10.1056/NEJMoa021274
Acknowledgment
This study was supported by an unrestricted grant from Glaxo Smith Kline laboratories.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Janin, S., Meneveau, N., Mahemuti, A. et al. Safety and efficacy of fondaparinux as an adjunctive treatment to thrombolysis in patients with high and intermediate risk pulmonary embolism. J Thromb Thrombolysis 28, 320–324 (2009). https://doi.org/10.1007/s11239-008-0288-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-008-0288-9